edotreotide has been researched along with Injuries, Radiation in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Paganelli, G; Rocca, P | 1 |
| Arnold, R; Bartenstein, P; Bouterfa, H; Buchholz, HG; Förster, GJ; Göke, B; Haus, U; Helisch, A; Pauwels, S; Reber, H; Weber, MM; Wiedenmann, B | 1 |
| Barone, R; Borson-Chazot, F; Chauvin, F; Gogou, L; Jamar, F; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S | 1 |
| Herrmann, R; Mäcke, HR; Müller-Brand, J; Otte, A | 1 |
| Brunner, FP; Maecke, HR; Mihatsch, MJ; Moll, S; Mueller-Brand, J; Nickeleit, V | 1 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
1 review(s) available for edotreotide and Injuries, Radiation
| Article | Year |
|---|---|
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Topics: Animals; Humans; Kidney Diseases; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2004 |
3 trial(s) available for edotreotide and Injuries, Radiation
| Article | Year |
|---|---|
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes | 2003 |
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Topics: Body Burden; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Injuries; Radiation Protection; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Risk Assessment; Risk Factors; Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 2004 |
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Topics: Adult; Aged; Algorithms; Body Burden; Dose-Response Relationship, Radiation; Female; Gastrointestinal Neoplasms; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Pancreatic Neoplasms; Radiation Injuries; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2005 |
3 other study(ies) available for edotreotide and Injuries, Radiation
| Article | Year |
|---|---|
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Topics: Female; Follow-Up Studies; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pilot Projects; Prospective Studies; Radiation Injuries; Radionuclide Imaging; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome; Yttrium Radioisotopes | 1999 |
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
Topics: Biopsy; Carcinoma, Neuroendocrine; Female; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Octreotide; Radiation Injuries; Thrombosis; Yttrium Radioisotopes | 2001 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |